Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
disitamab vedotin + zimberelizumab
- Development stage
- Preclinical
- Lead developer
- RemeGen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
disitamab vedotin + zimberelizumab is a combination therapy under investigation for the treatment of HER2-expressing cancers, particularly locally advanced or metastatic urothelial carcinoma. disitamab vedotin is a HER2-directed antibody-drug conjugate (ADC) that delivers the cytotoxic agent monomethyl auristatin E (MMAE) to tumor cells expressing HER2, while zimberelizumab is an investigational PD-1 inhibitor intended to block immune checkpoint signaling and enhance anti-tumor immune responses. The combination aims to leverage both targeted cytotoxicity and immune activation for improved efficacy in cancer treatment[3][5][7].
- Brand names
- AidexiYuquanyi
- Other names
- RC-48 + GLS-010disitamab vedotin combined with zimberelizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on disitamab vedotin + zimberelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on disitamab vedotin + zimberelizumab.